Gemcitabine - Accord Healthcare

Drug Profile

Gemcitabine - Accord Healthcare

Alternative Names: Gemcitabine hydrochloride - Accord Healthcare

Latest Information Update: 17 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Accord Healthcare
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 17 Aug 2017 Chemical structure information added
  • 03 Aug 2017 Registered for Breast cancer (Combination therapy, Metastatic disease) in USA (IV)
  • 03 Aug 2017 Registered for Non-small cell lung cancer (Combination therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top